Acadia Pharma (ACAD) Misses Q3 EPS by 5c
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $27.58 -1.57%
EPS Growth %: -52.4%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -52.4%
Financial Fact:
Net loss: -71.61M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q3 EPS of ($0.61), $0.05 worse than the analyst estimate of ($0.56). Revenue for the quarter came in at $5.3 million versus the consensus estimate of $2.9 million.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- Canaan Inc. (CAN) PT Lowered to $2 at BTIG
- Chime to acquire Stride Bank for $590M in cash
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
